83 FR 12584 - Findings of Research Misconduct
DEPARTMENT OF HEALTH AND HUMAN SERVICES Federal Register Volume 83, Issue 56 (March 22, 2018)
Federal Register Volume 83, Issue 56 (March 22, 2018)
| Page Range | 12584-12585 | |
| FR Document | 2018-05774 |
[Federal Register Volume 83, Number 56 (Thursday, March 22, 2018)] [Notices] [Pages 12584-12585] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-05774] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Findings of Research Misconduct AGENCY: Office of the Secretary, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: Findings of research misconduct have been made on the part of Bhagavathi Narayanan, Ph.D., former Research Associate Professor, Department of Environmental Medicine, New York University (NYU). Dr. Narayanan engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grants R03 CA107813, R01 CA106296, R01 CA106296-05S1, R03 CA133929, and P30 CA017613. The administrative actions, including debarment for a period of three (3) years, were implemented beginning on February 26, 2018, and are detailed below. FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr. P.H., Interim Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200. SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Bhagavathi Narayanan, Ph.D., New York University: Based on the report of an investigation conducted by NYU and analysis conducted by ORI in its oversight review, ORI found that Dr. Bhagavathi Narayanan, former Research Associate Professor, Department of Environmental Medicine, NYU, engaged in research misconduct in research supported by NCI, NIH, grants R03 CA107813, R01 CA106296, R01 CA106296-05S1, R03 CA133929, and P30 CA017613. ORI found that Respondent engaged in research misconduct by knowingly and intentionally falsifying and/or fabricating data reported in the following three (3) published papers and seven (7) grant applications submitted to NIH:Clin. Cancer Res. 9:3503-3513, 2003 (hereafter referred to as ``Clin. Cancer Res. 2003'') Anticancer Res. 31(12):4347-4358, 2011 (hereafter referred to as ``Anticancer Res. 2011'') Int. J. Oncol. 40:13-20, 2012 (hereafter referred to as ``Int. J. Oncol. 2012'') R01 CA163381-01 R01 CA138741-01A1 R01 CA106296-06A1 R01 CA106296-06A2 R03 CA158253-01A1 R21 CA170314-01 R01 ES024139-01 ORI found that Respondent fabricated and/or falsified Western blot data for protein expression levels in cancer tissues and/or cells in fifty-eight (58) blot panels included in twenty-two (22) figures reported in three (3) papers and seven (7) grant applications submitted to NIH. In the absence of valid Western blot images, the quantitative data presented in associated bar graphs and statistical analyses also are false. Specifically, Respondent trimmed and/or copied Western blot images from unrelated sources, manipulated them to obscure their origin, and reused and relabeled them to represent different experimental results in: Figures 5C, 6C, and 7C in Clin. Cancer Res. 2003 Figures 2c, 4b, 6a, and 6b in Int. J. Oncol. 2012 Figure 2B in Anticancer Res. 2011, also as Figure 1C in R01 CA163381-01 Figure 2A in Anticancer Res. 2011, also as Figure 1B in R01 CA163381-01 Figure 5D in Anticancer Res. 2011, also as Figure 8 in R01 CA163381-01 Figure 1A in R01 CA163381-01 Figure 6 in R01 CA138741-01A1 Figure 4 in R01 CA106296-06A1 Figure 4 in R01 CA106296-06A2 Figures 3 and 6 in R03 CA158253-01A1 Figures 3 and 4 in R21 CA170314-01 Figures 8A and 8B in R01 ES024139-01 Dr. Narayanan entered into a Voluntary Exclusion Agreement and voluntarily agreed, beginning on February 26, 2018: (1) To exclude herself for a period of three (3) years from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as ``covered transactions'' pursuant to [[Page 12585]] HHS' Implementation (2 CFR part 376) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the ``Debarment Regulations''); (2) to exclude herself voluntarily from serving in any advisory capacity to the U.S. Public Health Service (PHS) including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years; and (3) as a condition of the Agreement, to the retraction of Anticancer Res. 31(12):4347-4358, 2011 (PMID: 22199300), and will request that this paper be retracted. Wanda K. Jones, Interim Director, Office of Research Integrity. [FR Doc. 2018-05774 Filed 3-21-18; 8:45 am] BILLING CODE 4150-31-P
![12584 Federal Register / Vol. 83, No. 56 / Thursday, March 22, 2018 / Notices
of the nomination package submitted for membership. Candidates who are following three (3) published papers
each individual being nominated: selected for appointment to the and seven (7) grant applications
(1) A nomination letter clearly stating: committee are required to provide submitted to NIH:
a. Name and affiliation of the detailed information concerning such • Clin. Cancer Res. 9:3503–3513, 2003
nominee; matters as financial holdings, (hereafter referred to as ‘‘Clin. Cancer
b. qualifications of the nominee consultancies, and research grants or Res. 2003’’)
related to the focus area(s) described contracts for an ethics analysis to be • Anticancer Res. 31(12):4347–4358,
above (i.e., specific attributes which conducted to identify potential conflicts 2011 (hereafter referred to as
qualify the nominee for service in this of interest. ‘‘Anticancer Res. 2011’’)
capacity); Dated: March 14, 2018. • Int. J. Oncol. 40:13–20, 2012 (hereafter
c. area (out of the three listed above) referred to as ‘‘Int. J. Oncol. 2012’’)
Gustavo Ceinos,
the nominee is interested in • R01 CA163381–01
representing based on his/her CDR, USPHS, Designated Federal Officer,
Chronic Fatigue Syndrome Advisory • R01 CA138741–01A1
experience and background; Committee. • R01 CA106296–06A1
d. statement that the nominee is • R01 CA106296–06A2
[FR Doc. 2018–05833 Filed 3–21–18; 8:45 am]
willing to serve as a member of the • R03 CA158253–01A1
BILLING CODE 4150–42–P
Committee; • R21 CA170314–01
(2) The nominator’s name, address, • R01 ES024139–01
and daytime telephone number;
DEPARTMENT OF HEALTH AND ORI found that Respondent fabricated
(3) The home and/or work address,
HUMAN SERVICES and/or falsified Western blot data for
telephone number, and email address of
protein expression levels in cancer
the individual being nominated; Findings of Research Misconduct
(4) A current copy of the nominee’s tissues and/or cells in fifty-eight (58)
curriculum vitae or resume. The vitae or AGENCY: Office of the Secretary, HHS. blot panels included in twenty-two (22)
resume may be condensed to highlight ACTION: Notice. figures reported in three (3) papers and
the experience of the nominee related to seven (7) grant applications submitted
the focus areas described above. SUMMARY: Findings of research to NIH. In the absence of valid Western
An individual may self-nominate to misconduct have been made on the part blot images, the quantitative data
be on the Committee. Federal employees of Bhagavathi Narayanan, Ph.D., former presented in associated bar graphs and
should not be nominated for Research Associate Professor, statistical analyses also are false.
consideration of appointment to this Department of Environmental Medicine, Specifically, Respondent trimmed
Committee. Nominations that do not New York University (NYU). Dr. and/or copied Western blot images from
contain all of the above information will Narayanan engaged in research unrelated sources, manipulated them to
not be considered. misconduct in research supported by obscure their origin, and reused and
Electronic submissions: Nomination National Cancer Institute (NCI), relabeled them to represent different
materials, including attachments, may National Institutes of Health (NIH), experimental results in:
be submitted electronically to cfsac@ grants R03 CA107813, R01 CA106296, • Figures 5C, 6C, and 7C in Clin. Cancer
hhs.gov. An email from the CFSAC R01 CA106296–05S1, R03 CA133929, Res. 2003
Support Team will be sent to the and P30 CA017613. The administrative • Figures 2c, 4b, 6a, and 6b in Int. J.
nominating individual or nominee to actions, including debarment for a Oncol. 2012
confirm receipt of the nomination. If the period of three (3) years, were • Figure 2B in Anticancer Res. 2011,
email confirmation is not received implemented beginning on February 26, also as Figure 1C in R01 CA163381–
within two working days, please call 2018, and are detailed below. 01
202–690–7650. FOR FURTHER INFORMATION CONTACT: • Figure 2A in Anticancer Res. 2011,
Regular, Express, or Overnight Mail: Wanda K. Jones, Dr. P.H., Interim also as Figure 1B in R01 CA163381–
Written documents may be submitted to Director, Office of Research Integrity, 01
the following addressee only: CDR 1101 Wootton Parkway, Suite 750, • Figure 5D in Anticancer Res. 2011,
Gustavo Ceinos, MPH, Designated Rockville, MD 20852, (240) 453–8200. also as Figure 8 in R01 CA163381–01
Federal Officer, CFSAC, Office on SUPPLEMENTARY INFORMATION: Notice is • Figure 1A in R01 CA163381–01
Women’s Health, Office of the Assistant hereby given that the Office of Research • Figure 6 in R01 CA138741–01A1
Secretary for Health, Department of Integrity (ORI) has taken final action in • Figure 4 in R01 CA106296–06A1
Health and Human Services, 200 the following case: • Figure 4 in R01 CA106296–06A2
Independence Ave. SW, Room 728F6, Bhagavathi Narayanan, Ph.D., New • Figures 3 and 6 in R03 CA158253–
Washington, DC 20201. York University: Based on the report of 01A1
Telephone and facsimile submissions an investigation conducted by NYU and • Figures 3 and 4 in R21 CA170314–01
cannot be accepted. analysis conducted by ORI in its • Figures 8A and 8B in R01 ES024139–
The Department makes every effort to oversight review, ORI found that Dr. 01
ensure that the membership of federal Bhagavathi Narayanan, former Research Dr. Narayanan entered into a
advisory committees is fairly balanced Associate Professor, Department of Voluntary Exclusion Agreement and
in terms of points of view represented. Environmental Medicine, NYU, engaged voluntarily agreed, beginning on
Appointment to this Committee shall be in research misconduct in research February 26, 2018:
made without discrimination on the supported by NCI, NIH, grants R03 (1) To exclude herself for a period of
daltland on DSKBBV9HB2PROD with NOTICES
basis of age, race, ethnicity, gender, CA107813, R01 CA106296, R01 three (3) years from any contracting or
sexual orientation, disability, and CA106296–05S1, R03 CA133929, and subcontracting with any agency of the
cultural, religious, or socioeconomic P30 CA017613. United States Government and from
status. Nominations must state that the ORI found that Respondent engaged eligibility or involvement in
nominee is willing to serve as a member in research misconduct by knowingly nonprocurement programs of the United
of CFSAC and appears to have no and intentionally falsifying and/or States Government referred to as
conflict of interest that would preclude fabricating data reported in the ‘‘covered transactions’’ pursuant to
VerDate Sep<11>2014 19:32 Mar 21, 2018 Jkt 244001 PO 00000 Frm 00025 Fmt 4703 Sfmt 4703 E:\FR\FM\22MRN1.SGM 22MRN1](https://thefederalregister.org/doc/83_FR_12640/page/1.svg)
![Federal Register / Vol. 83, No. 56 / Thursday, March 22, 2018 / Notices 12585
HHS’ Implementation (2 CFR part 376) Emphasis Panel; Maintain and Enrich Place: National Institutes of Health, One
of OMB Guidelines to Agencies on Resource Infrastructure for Existing Democracy Plaza, 6701Democracy Boulevard,
Governmentwide Debarment and Environmental Epidemiology Cohorts. Suite 703, Bethesda MD 20892.
Date: April 11, 2018. Contact Person: Mary A. Kelly, Scientific
Suspension, 2 CFR part 180 (collectively Review Specialist, National Institute of
Time: 10:30 a.m. to 3:30 p.m.
the ‘‘Debarment Regulations’’); Nursing Research, National Institutes of
Agenda: To review and evaluate grant
(2) to exclude herself voluntarily from Health, 6701 Democracy Boulevard, Suite
applications.
serving in any advisory capacity to the Place: NIEHS/National Institutes of Health, 703, Bethesda, MD 20892, (301) 594–9695,
U.S. Public Health Service (PHS) Keystone Building, 530 Davis Drive, Room mary.kelly@nih.gov.
including, but not limited to, service on 1002, Research Triangle Park, NC 27709 This notice is being published less than 15
any PHS advisory committee, board, (Telephone Conference Call). days prior to the meeting due to the timing
and/or peer review committee, or as a Contact Person: Linda K. Bass, Scientific limitations imposed by the review and
consultant for a period of three (3) years; Review Officer, Scientific Review Branch, funding cycle.
and Division of Extramural Research and (Catalogue of Federal Domestic Assistance
(3) as a condition of the Agreement, Training, Nat. Institute of Environmental Program Nos. 93.361, Nursing Research,
to the retraction of Anticancer Res. Health Science, P.O. Box 12233, MD K3–03, National Institutes of Health, HHS)
31(12):4347–4358, 2011 (PMID: Research Triangle Park, NC 27709, (919) 541– Dated: March 16, 2018.
22199300), and will request that this 1307.
Sylvia L. Neal,
paper be retracted. (Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk Program Analyst, Office of Federal Advisory
Wanda K. Jones, Estimation—Health Risks from Committee Policy.
Interim Director, Office of Research Integrity. Environmental Exposures; 93.142, NIEHS [FR Doc. 2018–05850 Filed 3–21–18; 8:45 am]
[FR Doc. 2018–05774 Filed 3–21–18; 8:45 am] Hazardous Waste Worker Health and Safety BILLING CODE 4140–01–P
Training; 93.143, NIEHS Superfund
BILLING CODE 4150–31–P
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower DEPARTMENT OF HOMELAND
Development in the Environmental Health
DEPARTMENT OF HEALTH AND SECURITY
Sciences; 93.113, Biological Response to
HUMAN SERVICES Environmental Health Hazards; 93.114,
Federal Emergency Management
Applied Toxicological Research and Testing,
National Institutes of Health National Institutes of Health, HHS) Agency
Dated: March 16, 2018. [Docket ID: FEMA–2017–0014; OMB No.
National Institute of Environmental 1660–0016]
Health Sciences; Notice of Closed Natasha M. Copeland,
Meetings Program Analyst, Office of Federal Advisory Agency Information Collection
Committee Policy. Activities: Submission for OMB
Pursuant to section 10(d) of the [FR Doc. 2018–05849 Filed 3–21–18; 8:45 am]
Federal Advisory Committee Act, as Review; Comment Request; Revision
amended, notice is hereby given of the BILLING CODE 4140–01–P to National Flood Insurance Program
following meetings. Maps: Application Forms and
The meetings will be closed to the Instructions for LOMRs and CLOMRs
DEPARTMENT OF HEALTH AND
public in accordance with the AGENCY: Federal Emergency
HUMAN SERVICES
provisions set forth in sections Management Agency, DHS.
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., National Institutes of Health ACTION: Notice and request for
as amended. The grant applications and comments.
the discussions could disclose National Institute of Nursing Research;
confidential trade secrets or commercial Notice To Close Meeting SUMMARY: The Federal Emergency
property such as patentable material, Management Agency (FEMA), as part of
and personal information concerning Pursuant to section 10(d) of the its continuing effort to reduce
individuals associated with the grant Federal Advisory Committee Act, as paperwork and respondent burden,
applications, the disclosure of which amended, notice is hereby given of the invites the general public to take this
would constitute a clearly unwarranted following meeting. opportunity to comment on a
invasion of personal privacy. The meeting will be closed to the reinstatement, with change, of a
Name of Committee: National Institute of public in accordance with the previously approved information
Environmental Health Sciences Special provisions set forth in sections collection for which approval has
Emphasis Panel; NIH Support of R13 Grant 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., expired. FEMA will submit the
Applications. information collection abstracted below
Date: April 5, 2018.
as amended. The grant applications and
to the Office of Management and Budget
Time: 8:00 a.m. to 5:00 p.m. the discussions could disclose
for review and clearance in accordance
Agenda: To review and evaluate grant confidential trade secrets or commercial
with the requirements of the Paperwork
applications. property such as patentable material,
Reduction Act of 1995. The submission
Place: NIEHS/National Institutes of Health, and personal information concerning
Building 4401, East Campus, 79 T.W. will describe the nature of the
individuals associated with the grant
Alexander Drive, Research Triangle Park, NC information collection, the categories of
applications, the disclosure of which
27709 (Telephone Conference Call). respondents, the estimated burden (i.e.,
would constitute a clearly unwarranted
Contact Person: Janice B. Allen, Ph.D., the time, effort and resources used by
invasion of personal privacy.
daltland on DSKBBV9HB2PROD with NOTICES
Scientific Review Officer, Scientific Review respondents to respond) and cost, and
Branch, Division of Extramural Research and Name of Committee: National Institute of the actual data collection instruments
Training, Nat. Institute of Environmental Nursing Research Special Emphasis Panel; FEMA will use.
Health Science, P.O. Box 12233, MD EC–30/ Loan Repayment Review.
Room 3170 B, Research Triangle Park, NC DATES: Comments must be submitted on
Date: March 26, 2018.
27709, (919) 541–7556. Time: 1:00 p.m. to 2:00 p.m. or before April 23, 2018.
Name of Committee: National Institute of Agenda: To review and evaluate grant ADDRESSES: Submit written comments
Environmental Health Sciences Special applications. on the proposed information collection
VerDate Sep<11>2014 19:32 Mar 21, 2018 Jkt 244001 PO 00000 Frm 00026 Fmt 4703 Sfmt 4703 E:\FR\FM\22MRN1.SGM 22MRN1](https://thefederalregister.org/doc/83_FR_12640/page/2.svg)
Document Created: 2018-03-22 01:24:49
Document Modified: 2018-03-22 01:24:49
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Wanda K. Jones, Dr. P.H., Interim Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200. | |
| FR Citation | 83 FR 12584 |
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR